Monitored subject
Biotech Brief
Material shifts in drug development, clinical evidence, regulation, therapeutic platforms, manufacturing and the biotech industry.
Monitoring keywords
biotechbiotechnologybiopharmapharmaceuticaldrugtherapytherapeuticclinical trialclinical dataphase 1phase 2phase 3regulatory approvaldrug approvalbiologicbiosimilargene therapycell therapyCRISPRgene editingRNAmRNAantibodyvaccineoncologyrare diseaseGLP-1drug discoverydrug manufacturing
Latest briefings
FDA expands gene therapy and cell therapy approvals in sickle cell
FDA approved Casgevy for younger sickle cell patients and TREGZI to improve GVHD outcomes, reinforcing gene/cell therapy momentum.
FDA gene therapy leadership shift amid continued regulatory debate
FDA gene therapy leadership is changing as CBER flexibility debates persist, while approvals and manufacturing-focused pilots signal operational evolution for biotech.